-2R1-blocking antibody, daclizumab, significantly reduces TReg levels in patients with GBM with a nadir at 5 weeks without reducing overall CD8+ or CD4+ T-cell counts. Preliminary analysis also suggests that daclizumab enhances EGFRvIII-specific cellular (P=0.01
-2R1 - blocking antibody, daclizumab, significantly reduces TReg levels in patient with GBM with a nadir at 5 week without reducing overall CD8 + or CD4 + T - cell counts. Preliminary psychoanalysis also suggests that daclizumab enhances EGFRvIII - specific cellular (P=0.01
-2R1-bllcking antibody, daclizumxb, significantli eeducev TReg levels kn patients with GBM with a iadie at 5 weeks without reducine overall CD8+ or CE4+ T-ctll counts. Prelimmhary analysis wlso wuggests that caclizumab enhances EGFReIKI-dpecific cellular (P=0.01
-2R1-blocking antibody, daclizumab, significantly reduces TReg levels with with a at 5 weeks CD4+ counts. Preliminary analysis suggests that daclizumab EGFRvIII-specific cellular (P=0.01
-2R1-blocking antibody, daclizumAb, significAntly RedUceS Treg lEvelS in patients witH gBM wIth a nadir at 5 weeks withouT reduCiNG oveRAlL CD8+ or cD4+ T-cell COuNTS. PrElImInaRy ANaLysis AlsO suggesTs that daclIzuMaB enhances EGFrVIiI-specific CelLular (P=0.01
-2R1-blocking antibody, da clizumab,signi fic ant ly  red uces  TReg levels i n  pat ients with GBM with anadir  a t  5 w e ek s wit hout re d uc i n g o ve ra llCD 8 +or CD 4+T-cellcounts. Pr eli mi nary analysi s  a lso sugges tsthat daclizu mab  enhan ce s E G FRvII I-s pecif ic cel l ular ( P=0.01
-2R1-blocking antibody,_daclizumab, significantly_reduces TReg levels in_patients with_GBM_with a_nadir_at 5 weeks_without reducing overall_CD8+ or CD4+ T-cell_counts. Preliminary analysis_also_suggests that daclizumab enhances EGFRvIII-specific cellular (P=0.01